Latest Regulatory News

ikeGPS Group reports a robust first half of FY26 with a 47% increase in subscription revenue exit run rate and launches AI-driven PolePilot™ to boost productivity and ARPU.

Great Northern Minerals Limited has issued a prospectus for an underwritten offer of up to 10,000 listed options at an exercise price of $0.02 each, aiming to facilitate their quotation and trading on the ASX.

Riedel Resources has finalized drilling plans for its high-grade Kingman Gold Project in Arizona and secured $1.4 million through equity raises to fund upcoming exploration and development activities.

Golden Dragon Mining Ltd is set to raise $5 million through an IPO, aiming for ASX listing with a portfolio of promising gold and nickel exploration projects in Western Australia.

Brazilian Critical Minerals has reported exceptional results from its in-situ recovery trials at the Ema rare earth project, achieving rare earth concentrations far exceeding in-situ grades and securing strong local government backing.

Aldoro Resources has confirmed a substantial inferred mineral resource at its Kameelburg Rare Earth Element and Niobium project in Namibia, with Phase II drilling underway targeting high-grade zones. The company also moves to streamline its portfolio by divesting non-core assets.

Central Iron Ore Limited has filed an updated NI 43-101 Technical Report for its British King Gold Project in Western Australia, revealing a significant resource upgrade and confirming strong metallurgical performance.

Red Sky Energy reports steady production and cash flow growth from its Innamincka and Killanoola projects, while securing a strategic 35% stake in Angola’s Block 6/24, marking a significant step in its international expansion.

Pantera Lithium has completed the sale of its Smackover Lithium Project to EnergyX for A$40 million, securing cash and stock that bolster its balance sheet and strategic focus on US critical minerals.

Coast Entertainment’s Dreamworld development application has been called-in by the Queensland Minister, while the company reports robust FY26 trading growth and nears completion of its new King Claw ride.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Cazaly Resources has addressed a sharp rise in its share price and trading volume, attributing the movement to strong gold and silver prices alongside a recent independent research report.